PLK3 gRNA (BRDN0001146265) Citations (1)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal

---

Articles Citing PLK3 gRNA (BRDN0001146265)

Articles
The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3. Vaughan CA, Singh S, Subler MA, Windle JJ, Inoue K, Fry EA, Pillappa R, Grossman SR, Windle B, Andrew Yeudall W, Deb SP, Deb S. Nat Commun. 2021 Jan 29;12(1):704. doi: 10.1038/s41467-021-20928-8. PubMed

If you have published an article using this material, please email us at to have your article added to this page.